I-Mab

I-Mab Biopharma (Third Venture Biopharma) was initially founded by a senior innovative drug R&D team led by Dr. Zang Jingwu, together with China's listed company Tigermed and Baijiahui Technology Co., Ltd., and is a technology enterprise under Nanjing's "321 Talent Program".
The company completed its Series A financing in 2016, and in March 2017 merged with Tianshizhen Biotech to form I-Mab Biopharma (Shanghai) Co., Ltd., while completing a Series B financing led by C-Bridge Capital, raising US$150 million.
Based in China, the company develops innovative therapeutic antibody drugs for the global market, focusing on oncology immunology and autoimmune diseases. The R&D team has an average of ten years of senior R&D, discovery management, and project management experience in multinational pharmaceutical companies and local pharmaceutical enterprises.
The company's core competitiveness lies in its advantages in innovative drug target biology and molecular structure R&D of innovative antibody drugs, as well as in translational medicine research and clinical studies of innovative drugs. The company's strategy for innovative drug development is to rely on independent R&D, leverage technology collaboration with domestic and international research institutions and biotech companies, and, through international cooperation, introduce or co-develop innovative biologics for diseases with high incidence and difficulty in treatment in China.
The company's current innovative drug pipeline includes 12 projects of innovative antibodies and fusion protein drugs under development, among which two leading projects filed for clinical study in 2017 and initiated clinical research in Taiwan, South Korea, and China; other projects have entered the cell line or process development stage. The company's independently developed innovative bispecific antibodies will also enter the process development stage.
Since its inception, the company has established extensive international collaborations, such as the recent exclusive introduction and development of Olamkicept in partnership with Switzerland's FERRING company. The company's globally innovative projects will enter the clinical trial application stage in China and the United States in 2018, with plans to initiate Phase I clinical studies in both regions.
I-Mab's headquarters and R&D center are located in Shanghai Zhangjiang Hi-Tech Park, with registration and clinical affairs offices in Beijing.